Kiromic Biopharma, Inc.: Nasdaq/NYSE listing notice — Kiromic BioPharma receives Nasdaq delisting notice for bid price non-compliance; intends to request hearing

Kiromic Biopharma, Inc.

Nasdaq notified Kiromic on March 14, 2023 that it failed to regain minimum $1.00 bid price by March 13 grace period.
Common stock (KRBP) scheduled for delisting on March 23, 2023 unless hearing is requested.
Company intends to request hearing to stay delisting and present compliance plan.
Hearing panel may also consider separate $2.5M stockholders' equity deficiency as additional basis for delisting.
Panel can grant extension up to September 11, 2023; no assurance of continued listing.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Kiromic Biopharma, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

March 14, 2023, Kiromic Biopharma, Inc. (the “Company”) received written notice (the “ Notice ”) from The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that the Company did not maintain a minimum bid price of at least $1.00 for a minimum of ten (10) consecutive business days before the end of the Nasdaq grace period and, therefore, did not regain compliance with Listing Rule 5550(a)(2) by March 13, 2023, as required. As a result of the foregoing, the Staff informed the Company that its common stock would be subject to delisting from The Nasdaq Capital Market on March 23, 2023, unless the Compan

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-23-034000

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.